Revenue | $100 - $500 million See Exact Annual Revenue |
---|---|
Employees | 500 - 1,000Exact Company Size |
Primary Industry | 5417 Scientific Research & Development Services |
Address | 400 Dexter Avenue North Suite 1200 Seattle, WA 98109 |
Juno Therapeutics | Revenue Est. ($ Million) | Growth Rate (%) | # Employees |
---|---|---|---|
2023 | $100 - $500 million Details in Premium Report | ||
2022 | |||
2021 | |||
2020 | |||
2019 |
1-Year Growth Rate: 3-Year Growth Rate (CAGR): |
Juno Therapeutics P&L | $ Millions |
---|---|
Revenue (Sales) | |
Cost of Goods Sold | |
Gross Profit | |
Operating Expenses | |
Advertising | |
Salaries and wages | |
Other Operating Expenses | |
Total Operating Expenses | |
Operating Income | |
EBITDA | |
EBIT (Earnings Before Interest and Taxes) | |
Net Profit | |
Date | Investors | Percent Raised | Target Size |
---|---|---|---|
October 5, 2017 | 1 | 100% | $31 MM |
Complete list of funding rounds and total amounts in the Company Report |
Trademark | Date |
---|---|
KONFIRI Pharmaceutical preparations for the treatment of cancer and auto-immune diseases; pharmaceutical preparations for the treatment of lymphoma; pharmaceutical preparations for inhibiting cytokine production; pharmaceutical preparations that modulate the immune system; cells for medical or clinical use; diagnostic kits consisting primarily of cells for medical or clinical use | 05/13/2020 |
BREYANZI Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of lymphoma; pharmaceutical preparations that modulate the immune system; pharmaceutical preparations, namely, preparations for use in the treatment of tumors; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy | 08/07/2019 |
LISO-CEL Pharmaceutical preparations for the treatment of cancer and auto-immune diseases; pharmaceutical preparations for inhibiting cytokine production; pharmaceutical preparations that modulate the immune system; cells for medical or clinical use; diagnostic kits consisting primarily of cells for medical or clinical use | 12/08/2017 |
Company | Headquarters | Revenue ($ MM) |
---|---|---|
LEIDOS | Denver, CO | 100 |
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA | Albuquerque, NM | 30 |
INC RESEARCH | Raleigh, NC | 27 |
RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK | Albany, NY | 17 |
FLUOR MARINE PROPULSION | West Mifflin, PA | 15 |
SYNEOS HEALTH | Raleigh, NC | 13 |
ILLUMINA | San Diego, CA | 12 |
UT-BATTELLE | Oak Ridge, TN | 11 |
PRA HOLDINGS | Raleigh, NC | 11 |
Company | Headquarters | Revenue ($ MM) |
---|---|---|
FRED HUTCHINSON CANCER CENTER | Seattle, WA | 100 |
ADAPTIVE BIOTECHNOLOGIES | Seattle, WA | 14 |
ALLEN INSTITUTE | Seattle, WA | 13 |
JUNO THERAPEUTICS | Seattle, WA | 13 |
SANA BIOTECHNOLOGY | Seattle, WA | 9 |
ULTRA SAFE NUCLEAR | Seattle, WA | 5 |
Company | Revenue ($ MM) |
---|---|
|